

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

| | |
|-------------------|--|
| Program Number | 2025 P 3039-18 |
| Program | Step Therapy |
| Medications | *Actemra® (tocilizumab), Actemra (tocilizumab) ACTPen, and Tyenne® (tocilizumab-aazg) *This step criteria refers to the subcutaneous formulations of tocilizumab. |
| P&T Approval Date | 10/2014, 2/2015, 3/2016, 3/2017, 3/2018, 3/2019, 9/2019, 12/2020, 12/2021, 11/2022, 1/2023, 4/2023, 2/2024, 10/2024, 12/2024, 4/2025 |
| Effective Date | 6/1/2025 |

1. Background:

Step therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. This program requires a member to try two preferred products before providing coverage for Actemra (tocilizumab) or Tyenne (tocilizumab-aazg). Infused medications approved for the treatment of rheumatoid arthritis are not part of the criteria.

Actemra (tocilizumab) and Tyenne (tocilizumab-aazg) are interleukin-6 (IL-6) receptor antagonists indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab is tumor necrosis factor (TNF) blocker indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Cimzia® (certolizumab) and Simponi® (golimumab), both TNF blockers, are indicated for the treatment of adults with moderately to severely active rheumatoid arthritis. Rinvoq (upadacitinib) and Xeljanz/Xeljanz XR (tofacitinib) are JAK inhibitors indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an adequate response or intolerance to methotrexate. Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis.

Members currently on Actemra or Tyenne therapy as documented in claims history will be allowed to continue on their current therapy. Members new to therapy will be required to meet the coverage criteria below.

2. Coverage Criteria^a:

A. Rheumatoid Arthritis (RA)

1. Actemra or Tyenne will be approved based on **both** of the following criteria:

a. Diagnosis of moderately to severely active rheumatoid arthritis

-AND-

b. **One** of the following:

(1) History of failure, contraindication, or intolerance to **two** of the following preferred products (Document drug, date, and duration of trial):

- (a) One of the preferred adalimumab products^b
- (b) Cimzia (certolizumab)
- (c) Enbrel (etanercept)
- (d) Rinvoq (upadacitinib)
- (e) Simponi (golimumab)
- (f) Xeljanz/Xeljanz XR (tofacitinib)

-OR-

(2) **Both** of the following:

(a) Patient is currently on Actemra or Tyenne therapy

-AND-

(b) Patient has **not** received a manufacturer supplied sample at no cost in the prescriber's office, or any form of assistance from a manufacturer sponsored program (e.g., sample card which can be redeemed at a pharmacy for a free supply of medication) as a means to establish as a current user of Actemra or Tyenne*

* Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from a manufacturer sponsored program **shall be required** to meet initial authorization criteria as if patient were new to therapy.

Authorization will be issued for 12 months.

B. Other Diagnoses

1. Actemra or Tyenne will be approved

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization

management programs may apply.

^b For a list of preferred products please reference drug coverage tools.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits and/or Notification may be in place.
- The intravenous infusion is typically covered under the medical benefit. Please refer to the United Healthcare Drug Policy for Tocilizumab.

4. References:

1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; September 2024.
2. Humira [package insert]. North Chicago, IL: AbbVie Inc.; February 2021.
3. Cimzia [package insert]. Smyrna, GA: UCB, Inc.; September 2019.
4. Simponi [package insert]. Horsham, PA: Janssen Biotech, Inc.; September 2019.
5. Rinvoq [package insert]. North Chicago, IL: AbbVie Inc.; April 2022.
6. Xeljanz/Xeljanz XR/Xeljanz Oral Solution [package insert]. New York, NY: Pfizer Labs; January 2022.
7. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corp.; June 2022.
8. Tyenne [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2024

| Program | Step Therapy - Actemra (tocilizumab) and Tyenne (tocilizumab-aazg) |
|-----------------------|--|
| Change Control | |
| 10/2014 | New step therapy program. |
| 2/2015 | Reformatted to clarify intent. Updated sample pack language. |
| 3/2016 | Annual review. Updated background. Changed authorization periods from 60 months to 12 months. Added Maryland Continuation of Care. Added reference to UHC drug policy for intravenous infusions. Updated references. |
| 7/2016 | Added Indiana and West Virginia coverage information. |
| 11/2016 | Administrative change. Added California coverage information. |
| 3/2017 | Annual review. Updated coverage criteria to include manufacturer sample language (i.e., Actemra Access Solutions program); added verbiage to simplify initial authorization criteria. Updated coverage criteria to add documentation language of failure of preferred products (i.e., document drug, date and duration of trial). Updated background and references. State mandate reference language updated. |
| 3/2018 | Annual review with no updated to coverage criteria. Updated references. |
| 3/2019 | Annual review with no updates to coverage criteria. Updated references. |
| 9/2019 | Revised step therapy medications. Updated background and references. |
| 12/2020 | Annual review. Added ACTPen to medications in-scope for clarity. Specified diagnosis requirements to match other programs but no |

| | |
|---------|---|
| | change to clinical intent. Updated references. |
| 12/2021 | Annual review. Removed biologic language with no changes to clinical criteria. Updated background and references. |
| 11/2022 | Added Enbrel as a preferred product step option for RA. Updated references. |
| 1/2023 | Updated step therapy requirements to Humira or Amjevita. Updated background. |
| 4/2023 | Updated step therapy requirement from Humira or Amjevita to one of the preferred adalimumab products and added the footnote “For a list of preferred adalimumab products please reference drug coverage tools.” |
| 2/2024 | Removed Olumiant as a preferred product for RA. |
| 10/2024 | Updated RA step requirement noting Adalimumab-adaz (unbranded Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab products with no change to clinical intent. Removed preferred adalimumab footnote. |
| 12/2024 | Added Tyenne to coverage criteria with Actemra. Updated background and references. |
| 4/2025 | Removed examples for adalimumab step therapy. Added the footnote “For a list of preferred products please reference drug coverage tools.” |